DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Spain
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
FAE logo

Faes Farma, S.A. Stock Price

BME:FAE Community·€1.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

FAE Share Price Performance

€4.46
0.24 (5.57%)
​
€5.36
Fair Value
€4.46
0.24 (5.57%)
16.8% undervalued intrinsic discount
€5.36
Fair Value
Price €4.46
AnalystConsensusTarget €5.36
Fri, 31 Jul 26
Fair Value€5.36
Share Pricen/a

FAE Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €5.36 16.8% undervalued intrinsic discount

Latin American Expansion And Ophthalmology Integration Will Reshape This Pharma Group’s Future Profile

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
FAE logo
Faes Farma
16.8% undervalued intrinsic discount

Latin American Expansion And Ophthalmology Integration Will Reshape This Pharma Group’s Future Profile

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Published 31 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
FAE logo

Latin American Expansion And Ophthalmology Integration Will Reshape This Pharma Group’s Future Profile

Fair Value: €5.36 16.8% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet and pays a dividend.

2 Risks
4 Rewards
View Full Analysis

Faes Farma, S.A. Key Details

€711.1m

Revenue

€247.7m

Cost of Revenue

€463.4m

Gross Profit

€379.2m

Other Expenses

€84.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.27
65.17%
11.84%
57.0%
View Full Analysis

About FAE

Founded
1933
Employees
2611
CEO
Eduardo de la Cuadra
WebsiteView website
faesfarma.com

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. The company also provides animal nutrition and health products. It offers products for various therapeutic areas. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

Recent FAE News & Updates

User avatar
New Narrative • Jul 31

Latin American Expansion And Ophthalmology Integration Will Reshape This Pharma Group’s Future Profile

Catalysts About Faes Farma Faes Farma is a pharmaceutical and animal nutrition group with a growing international footprint, including Iberia, Latin America and ophthalmology operations through SIFI and Edol. What are the underlying business or industry changes driving this perspective?

Recent updates

No updates

Faes Farma, S.A. Competitors

GRF logo

Grifols

Symbol: BME:GRF
Market cap: €5.9b
ROVI logo

Laboratorios Farmaceuticos Rovi

Symbol: BME:ROVI
Market cap: €2.9b
ALM logo

Almirall

Symbol: BME:ALM
Market cap: €2.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide